Extended Data Fig. 3: Hepatic fat fraction, body weight and plasma glucose (Part A). | Nature Metabolism

Extended Data Fig. 3: Hepatic fat fraction, body weight and plasma glucose (Part A).

From: Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes

Extended Data Fig. 3: Hepatic fat fraction, body weight and plasma glucose (Part A).

a, Mean change from baseline to day 28 of treatment in fasting hepatic fat fraction measured by MRI-PDFF. Evaluable patients: placebo, n = 9; cotadutide, n = 10. Data are individual data points and means ± SD. * P < 0.01. b, Mean change from baseline to day 29 of treatment in body weight. Evaluable patients: placebo, n = 9; cotadutide, n = 10. Data are individual data points and means ± SD. ** P < 0.001. c, Mean change from baseline to day 28 of treatment in fasting plasma glucose. Mean change from baseline to day 28: placebo, ‒2.3 mg/dl (SD, 10.7); cotadutide, ‒44.5 mg/dl (SD, 34.5). Evaluable patients: placebo, n = 9; cotadutide, n = 10. Data are individual data points and mean (horizontal bar). Two-sided P-values from ANCOVA model adjusting for baseline value and treatment group are shown, with no corrections for multiple comparisons applied. MRI-PDFF, magnetic resonance imaging–estimated proton density fat fraction; SD, standard deviation.

Back to article page